News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,094 Results
Type
Article (14282)
Company Profile (281)
Press Release (254531)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79547)
Career Advice (153)
Deals (13234)
Drug Delivery (35)
Drug Development (50470)
Employer Resources (31)
FDA (5728)
Job Trends (5139)
News (144464)
Policy (10034)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21685)
ALS (69)
Alzheimer's disease (852)
Antibody-drug conjugate (ADC) (109)
Approvals (5755)
Artificial intelligence (134)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (60)
Brain cancer (20)
Breast cancer (162)
Cancer (1533)
Cardiovascular disease (121)
Career advice (134)
Career pathing (2)
CAR-T (126)
Cell therapy (346)
Cervical cancer (9)
Clinical research (41190)
Collaboration (566)
Compensation (283)
Complete response letters (13)
COVID-19 (1034)
CRISPR (44)
C-suite (173)
Cystic fibrosis (78)
Data (1630)
Denatured (11)
Depression (32)
Diabetes (144)
Diagnostics (1304)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (88)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (93)
Earnings (30202)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48837)
Executive appointments (477)
FDA (6507)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (521)
Gene editing (102)
Generative AI (10)
Gene therapy (271)
GLP-1 (374)
Government (1084)
Grass and pollen (2)
Guidances (73)
Healthcare (6595)
Huntington's disease (23)
IgA nephropathy (26)
Immunology and inflammation (100)
Indications (20)
Infectious disease (1101)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7282)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1386)
Liver cancer (34)
Lung cancer (209)
Lymphoma (105)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (65)
Medical device (2604)
Medtech (2605)
Mergers & acquisitions (6295)
Metabolic disorders (412)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (74)
Neuropsychiatric disorders (25)
Neuroscience (1281)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (22)
Obesity (199)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (124)
Partnered (8)
Patents (138)
Patient recruitment (83)
Peanut (35)
People (25691)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14556)
Phase II (19168)
Phase III (12099)
Pipeline (984)
Policy (49)
Postmarket research (852)
Preclinical (6165)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (299)
Real estate (1419)
Recruiting (12)
Regulatory (8680)
Reports (17)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (5)
RNA editing (6)
RSV (10)
Schizophrenia (64)
Series A (102)
Series B (70)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (217)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (154)
Last 7 days (593)
Last 30 days (1995)
Last 365 days (19361)
2025 (7273)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17358)
Australia (2946)
California (4131)
Canada (1186)
China (378)
Colorado (156)
Connecticut (157)
Delaware (110)
Europe (37370)
Florida (502)
Georgia (125)
Idaho (16)
Illinois (244)
India (10)
Indiana (94)
Iowa (2)
Japan (82)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (499)
Massachusetts (3287)
Michigan (75)
Minnesota (153)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1017)
New Mexico (12)
New York (1101)
North Carolina (573)
North Dakota (5)
Northern California (1849)
Ohio (116)
Oklahoma (9)
Oregon (21)
Pennsylvania (775)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1579)
Tennessee (25)
Texas (478)
United States (14066)
Utah (56)
Virginia (85)
Washington D.C. (31)
Washington State (364)
Wisconsin (18)
269,094 Results for "cyteir therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq - March 07, 2024
Cyteir Therapeutics, Inc. announced that it has formally notified The Nasdaq Stock Market of its intent to delist the Company’s common stock from the Nasdaq Global Select Market.
March 7, 2024
·
2 min read
Genetown
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor.
June 30, 2023
·
8 min read
Business
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights.
May 10, 2023
·
7 min read
Business
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO).
February 6, 2023
·
2 min read
Business
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent operational highlights.
March 23, 2023
·
8 min read
Genetown
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer.
January 19, 2023
·
7 min read
Business
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights.
November 7, 2022
·
8 min read
Genetown
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentation at the 2022 Jefferies Healthcare Conference.
May 31, 2022
·
1 min read
Business
Cyteir Therapeutics Names Adam Veness General Counsel
Cyteir Therapeutics, Inc., a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Adam Veness, Esq. has joined Cyteir as General Counsel.
April 25, 2022
·
2 min read
Business
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent operational highlights.
August 8, 2022
·
9 min read
1 of 26,910
Next
